Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Bone loss is a common complication in patients before and after liver transplantation (LT). The aim of this study was to investigate the efficacy of prophylactic treatment with bisphosphonates after LT in preventing progressive bone loss in LT patients. We included 136 patients with end-stage liver diseases awaiting LT. Bone mineral density (BMD) (by dual X-ray absorptiometry) and markers of bone metabolism were determined before, and 4, 12, 24, 36, and 48 months after LT. All patients received vitamin D and calcium supplementation before and after LT, those with osteopenia or osteoporosis prior to LT were additionally treated with alendronate following LT. Decreased BMD was seen in a high percentage of patients undergoing LT (osteopenia 48.5%, osteoporosis 23.5%). Reduced BMD before LT was not related to gender, underlying liver disease, or Child-Turcotte-Pugh classification. Body mass index (BMI) prior to LT, however, correlated significantly with the fracture risk. Alendronate prevented the ubiquitously observed bone loss after LT in patients with osteoporosis and osteopenia and, in addition, led to an increase in BMD in patients with osteoporosis within 24 months after LT. In conclusion, our study suggests that alendronate is efficacious in preventing the natural course of bone loss associated with LT. (Liver Transpl 2005;11:960–966.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Eastell, R., Dickson, R. E., Hodgson, S. F., Wiesner, R. H., Porayko, M. K., Wahner, H. W., Cedel, S. L., Riggs, L. B., & Krom, R. A. F. (1991) · Hepatology · doi:10.1002/hep.1840140215 · Cited by 297
Gallego-Rojo, F. J., Gonzalez-Calvin, J. L., Muñoz-Torres, M., Mundi, J. L., Fernandez-Perez, R., & Rodrigo-Moreno, D. (1998) · Hepatology · doi:10.1002/hep.510280315 · Cited by 241
Bone disease after orthotopic liver transplantation
Haagsma, E. B., Thijn, C. J. P., Post, J. G., Slooff, M. J. H., & Gips, C. H. (1988) · Journal of Hepatology · doi:10.1016/s0168-8278(88)80467-7 · Cited by 112
Dodidou, P., Bruckner, T., Hosch, S., Haass, M., Klar, E., Sauer, P., Ziegler, R., & Leidig-Bruckner, G. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1315-x · Cited by 57
Regional bone mineral density after orthotopic liver transplantation
Hussaini, S. H., Oldroyd, B., Stewart, S. P., Roman, F., Smith, M. A., Pollard, S., Lodge, P., OʼGrady, J. G., & Losowsky, M. S. (1999) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199902000-00016 · Cited by 42
Cited by
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.024 · Cited by 1,130
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
“More than 50 different instruments are available for assessing QoL in liver transplant candidates or recipients, and among these, generic health assessment questionnaires are the most widely used [468].”
BackgroundInfluentialGuañabens, N., & Parés, A. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.05.030 · Cited by 71
Anastasilakis, A. D., Tsourdi, E., Makras, P., Polyzos, S. A., Meier, C., McCloskey, E. V., Pepe, J., & Zillikens, M. C. (2019) · Bone · doi:10.1016/j.bone.2019.07.006 · Cited by 71
Diagnosis and Management of Cirrhosis-Related Osteoporosis
Santos, L. A. A., & Romeiro, F. G. (2016) · BioMed Research International · doi:10.1155/2016/1423462 · Cited by 66
Management of osteoporosis in liver disease
Guañabens, N., & Parés, A. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.03.007 · Cited by 56
Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation
Bodingbauer, M., Wekerle, T., Pakrah, B., Roschger, P., Peck-Radosavljevic, M., Silberhumer, G., Grampp, S., Rockenschaub, S., Berlakovich, G., Steininger, R., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01844.x · Cited by 54
“Another investigator of an uncontrolled trial suggested that alendronate was efficacious in preventing bone loss associated with LT (13).”
BackgroundAtamaz, F., Hepguler, S., Akyildiz, M., Karasu, Z., & Kilic, M. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0082-5 · Cited by 46
“A recent prospective, long-term study also reported antifracture effects of ALN during the first 2 years after OLT [ 14 ].”
BackgroundMisof, B. M., Bodingbauer, M., Roschger, P., Wekerle, T., Pakrah, B., Haas, M., Kainz, A., Oberbauer, R., Mühlbacher, F., & Klaushofer, K. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9161-2 · Cited by 41
“Alendronate and zoledronic acid (ZOL) were successful in preventing bone loss after OLT [5, 15], and in a recent clinical study of prophylactic high-dose ZOL therapy after OLT we could prove the efficacy of this bisphosphonate in preventing also fractures in liver recipients [16].”
Background
Metadata
- Authors
- Millonig, G., Graziadei, I. W., Eichler, D., Pfeiffer, K.-P., Finkenstedt, G., Muehllechner, P., Koenigsrainer, A., Margreiter, R., & Vogel, W.
- Venue
- Liver Transplantation
- Published
- 2005-08
- Volume
- 11
- Issue
- 8
- Pages
- 960-966
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W2019612461
- Cited by
- 87
- References
- 6
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.